Obesity is a huge and increasing medical problem, with inadequate therapeutic options. One approach to the treatment of obesity is long-term pharmacotherapy. One modestly effective drug, orlistat, has been marketed in the United States since 1999. More recently other drugs have been approved by the FDA: lorcaserin and Qsymia (a combination of phentermine and topiramate) in 2012 and Contrave (a combination of buproprion and naltrexone) and liraglutide (high dose) in 2014. The limited efficacy of single agents has led to the idea that additional agents and combination therapy are required. Progress in FY2015 includes the following: In 2014 we published a re-examination of chemical uncoupler 2,4-dinitrophenol (DNP) as a treatment for obesity in mice. DNP was an effective and widely used weight loss drug in the early 1930s. DNP treatment increased energy expenditure but did not change food intake. DNP-treated mice weighed 26% less than controls after 2 months of treatment due to decreased fat mass, without a change in lean mass. DNP improved glucose tolerance and reduced hepatic steatosis without observed toxicity. DNP treatment also reduced brown adipose tissue activity, demonstrating that DNP-mediated heat generation substituted for brown adipose tissue thermogenesis. At 22 C, a typical vivarium temperature that is below thermoneutrality, DNP treatment had no effect on body weight, adiposity, or glucose homeostasis. Thus, environmental temperature should be considered when assessing an anti-obesity drug in mice, particularly agents acting on energy expenditure. Furthermore, the beneficial effects of DNP suggest that chemical uncouplers deserve further investigation for the treatment of obesity and its comorbidities. This year, we reported the effects of CL316243, a beta3-adrenergic agonist studied under similar conditions. To our surprise, the interaction between environmental temperature and CL316243 treatment is different from the interaction between environmental temperature and 2,4-dinitrophenol treatment reported previously, suggesting that each drug mechanism must be examined to understand the effect of environmental temperature on drug efficacy.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
Zip Code
Reitman, Marc L (2018) Of mice and men - environmental temperature, body temperature, and treatment of obesity. FEBS Lett 592:2098-2107
Jain, Shalini; Panyutin, Anna; Liu, Naili et al. (2018) Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors. Am J Physiol Endocrinol Metab 315:E357-E366
Xiao, Cuiying; Piñol, Ramón A; Carlin, Jesse Lea et al. (2017) Bombesin-like receptor 3 (Brs3) expression in glutamatergic, but not GABAergic, neurons is required for regulation of energy metabolism. Mol Metab 6:1540-1550
Reitman, Marc L (2017) How Does Fat Transition from White to Beige? Cell Metab 26:14-16
Reitman, Marc L (2016) Hormone-Replacement Therapy for Melanocyte-Stimulating Hormone Deficiency. N Engl J Med 375:278-9
Hall, Kevin D; Chen, Kong Y; Guo, Juen et al. (2016) Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr 104:324-33
Lateef, Dalya M; Xiao, Cuiying; Reitman, Marc L (2015) Search for an Endogenous Bombesin-Like Receptor 3 (BRS-3) Ligand Using Parabiotic Mice. PLoS One 10:e0142637
Xiao, Cuiying; Goldgof, Margalit; Gavrilova, Oksana et al. (2015) Anti-obesity and metabolic efficacy of the ?3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C. Obesity (Silver Spring) 23:1450-9
Chen, Kong Y; Muniyappa, Ranganath; Abel, Brent S et al. (2015) RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab 100:1639-45
Abreu-Vieira, Gustavo; Xiao, Cuiying; Gavrilova, Oksana et al. (2015) Integration of body temperature into the analysis of energy expenditure in the mouse. Mol Metab 4:461-70

Showing the most recent 10 out of 26 publications